Elicio Therapeutics
ELTX
37 hedge funds and large institutions have $16.6M invested in Elicio Therapeutics in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
32% more funds holding
Funds holding: 28 → 37 (+9)
0.19% more ownership
Funds ownership: 11.7% → 11.89% (+0.19%)
21% less capital invested
Capital invested by funds: $20.9M → $16.6M (-$4.32M)
89% less call options, than puts
Call options by funds: $291K | Put options by funds: $2.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$512K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$278K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$227K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$213K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$209K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$510K |
| 2 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
-$295K |
| 3 |
Millennium Management
New York
|
-$250K |
| 4 |
Renaissance Technologies
New York
|
-$187K |
| 5 |
Citigroup
New York
|
-$117K |
ELTX Hedge Fund Activity: Q4 2025 in Review
37 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q4 2025, worth a combined $16.6M — down 21% from $20.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ELTX positions and 4 closed out — a net gain of 9 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $512K. The largest seller was Susquehanna International Group, cutting an estimated $510K.
- 37 institutional investors held Elicio Therapeutics (ELTX) as of Q4 2025, up from 28 in Q3 2025.
- Funds reported $16.6M of Elicio Therapeutics stock for Q4 2025, down 21% quarter-over-quarter.
- 13 funds opened new Elicio Therapeutics positions in Q4 2025 and 4 closed out, a net change of +9 holders.
- The largest Elicio Therapeutics buyer in Q4 2025 was 683 Capital Management, an estimated $512K added.
- The largest Elicio Therapeutics seller in Q4 2025 was Susquehanna International Group, an estimated $510K sold.
Based on aggregated 13F filings for Q4 2025.